Predictors and Limitations of the Penetration Depth of Photodynamic Effects in the Rodent Brain.
Collin T InglutBrandon GaitanDaniel NajafaliIrati Abad LopezNina P ConnollySeppo OrsilaRobert PerttilaGraeme F WoodworthYu ChenHuang-Chiao HuangPublished in: Photochemistry and photobiology (2019)
Fluorescence-guided surgery (FGS) is routinely utilized in clinical centers around the world, whereas the combination of FGS and photodynamic therapy (PDT) has yet to reach clinical implementation and remains an active area of translational investigations. Two significant challenges to the clinical translation of PDT for brain cancer are as follows: (1) Limited light penetration depth in brain tissues and (2) Poor selectivity and delivery of the appropriate photosensitizers. To address these shortcomings, we developed nanoliposomal protoporphyrin IX (Nal-PpIX) and nanoliposomal benzoporphyrin derivative (Nal-BPD) and then evaluated their photodynamic effects as a function of depth in tissue and light fluence using rat brains. Although red light penetration depth (defined as the depth at which the incident optical energy drops to 1/e, ~37%) is typically a few millimeters in tissues, we demonstrated that the remaining optical energy could induce PDT effects up to 2 cm within brain tissues. Photobleaching and singlet oxygen yield studies between Nal-BPD and Nal-PpIX suggest that deep-tissue PDT (>1 cm) is more effective when using Nal-BPD. These findings indicate that Nal-BPD-PDT is more likely to generate cytotoxic effects deep within the brain and allow for the treatment of brain invading tumor cells centimeters away from the main, resectable tumor mass.
Keyphrases
- photodynamic therapy
- resting state
- white matter
- optical coherence tomography
- gene expression
- functional connectivity
- fluorescence imaging
- cerebral ischemia
- high resolution
- primary care
- cardiovascular disease
- squamous cell carcinoma
- minimally invasive
- coronary artery disease
- multiple sclerosis
- mass spectrometry
- blood brain barrier
- cancer therapy
- quality improvement
- young adults
- combination therapy
- lymph node metastasis